Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 29,385,726
  • Shares Outstanding, K 224,610
  • Annual Sales, $ 3,084 M
  • Annual Income, $ 399 M
  • 36-Month Beta 1.39
  • Price/Sales 9.46
  • Price/Cash Flow 21.63
  • Price/Book 3.35

Price Performance

See More
Period Period Low Period High Performance
1-Month
125.20 +4.50%
on 02/17/17
138.21 -5.34%
on 02/16/17
-1.14 (-0.86%)
since 01/20/17
3-Month
109.12 +19.90%
on 12/13/16
145.00 -9.77%
on 01/10/17
+13.81 (+11.80%)
since 11/22/16
52-Week
109.12 +19.90%
on 12/13/16
162.00 -19.24%
on 04/22/16
-14.49 (-9.97%)
since 02/22/16

Most Recent Stories

More News
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More

The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.

LGND : 103.27 (-1.94%)
BMRN : 89.79 (-0.50%)
ZTS : 53.38 (-0.17%)
SAGE : 61.93 (-3.33%)
TEVA : 35.97 (-1.86%)
ICPT : 122.79 (-2.12%)
ALXN : 130.83 (+0.72%)
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

CELG : 119.27 (-0.14%)
SRPT : 30.38 (+5.93%)
MDCO : 52.22 (-2.08%)
BMRN : 89.79 (-0.50%)
GILD : 68.83 (-0.66%)
AMGN : 172.61 (-0.31%)
ALXN : 130.83 (+0.72%)
Forget Alexion, Buy these 4 Biotech Stocks Instead

We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

CELG : 119.27 (-0.14%)
LGND : 103.27 (-1.94%)
EXEL : 22.62 (-2.12%)
FATE : 4.24 (-3.20%)
ALXN : 130.83 (+0.72%)
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS

Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.

IRWD : 16.87 (-1.46%)
EXAS : 22.69 (+1.25%)
ZTS : 53.38 (-0.17%)
MNTA : 15.10 (-5.92%)
TEVA : 35.97 (-1.86%)
ALXN : 130.83 (+0.72%)
Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y

Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.

EXAS : 22.69 (+1.25%)
SNSS : 4.25 (unch)
GSK : 41.03 (-1.44%)
ALXN : 130.83 (+0.72%)
Alexion (ALXN) Misses on Q4 Earnings and Revenues

Alexion missed on earnings expectations in the fourth quarter of 2016.

ALXN : 130.83 (+0.72%)
Alexion Reports Fourth Quarter and Full Year 2016 Results and Provides Financial Guidance for 2017

--Global Soliris(R) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS

ALXN : 130.83 (+0.72%)
5 Stocks to Watch that Report Earnings Tomorrow

Arista Networks ( ANET ): Arista Networks roared through 2016 only to hit a massive snag at the start of the new year. In late January, the CBP revoked an earlier court ruling over an ongoing patent infringement...

WEN : 13.69 (-3.11%)
MGM : 26.46 (-1.82%)
ANET : 121.80 (-0.67%)
H : 52.20 (-2.30%)
LVS : 51.97 (-0.13%)
SPY : 236.28 (-0.09%)
ALXN : 130.83 (+0.72%)
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More

The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.

AGIO : 48.99 (-2.80%)
RARE : 78.18 (+1.64%)
ZTS : 53.38 (-0.17%)
GILD : 68.83 (-0.66%)
REGN : 370.22 (-0.37%)
GSK : 41.03 (-1.44%)
SNY : 42.52 (-0.56%)
ALXN : 130.83 (+0.72%)
Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?

Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.

INCY : 121.36 (-0.82%)
ACOR : 25.25 (-0.20%)
AMAG : 23.90 (unch)
ALXN : 130.83 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system...

See More

Support & Resistance

2nd Resistance Point 133.36
1st Resistance Point 132.09
Last Price 130.83
1st Support Level 129.46
2nd Support Level 128.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.